Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Novo Nordisk ( (NVO) ) just unveiled an update.
Novo Nordisk announced the successful completion of its phase 1b/2a clinical trial for amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous administration to aid weight loss in individuals with overweight or obesity. The trial, which ended on January 24, 2025, demonstrated promising results, with participants experiencing significant weight loss compared to those on a placebo. This positions amycretin as a potential new treatment option, with further clinical development planned, reinforcing Novo Nordisk’s commitment to advancing treatments for obesity and related conditions.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It is focused on driving change to defeat chronic diseases, particularly in the realm of diabetes, through scientific breakthroughs, expanding access to medicines, and working towards prevention and cure. The company employs about 72,000 people and markets its products in around 170 countries.
YTD Price Performance: -7.34%
Average Trading Volume: 7,531,696
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $359.6B
For a thorough assessment of NVO stock, go to TipRanks’ Stock Analysis page.
